Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Metastatic Breast Cancer
NCT04699630Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of patritumab deruxtecan in breast cancer (3 arms), sponsored by SCRI Development Innovations. Primary endpoints: Overall Response Rate at 45 months and Progression-Free Survival at 6 Months. Started May 2021; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04699630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699630.